No. |
Drug (Description in trials) |
DrugBank |
KEGG DRUG * |
KEGG GENES * [Number of genes] |
KEGG PATHWAY [Number of pathways] |
Disease ID * [Number of diseases] |
1 |
0 mg prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 44 |
2 |
5 mg prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[1] 44 |
3 |
Abatacept |
Abatacept |
D03203 |
[2] CD80, CD86 |
[12] Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules (CAMs), Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis |
[24] 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 96, 97, 107, 164, 222, 271, 284, 285, 300 |
4 |
Avacopan |
Avacopan |
D11093 |
[1] C5AR1 |
[3] Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Staphylococcus aureus infection |
[4] 43, 44, 222, 223 |
5 |
Azathioprin-ratiopharm® 25 mg filmtabletten |
- |
- |
- |
- |
[1] 44 |
6 |
Azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
[18] 11, 13, 19, 35, 42, 43, 44, 45, 46, 49, 65, 66, 85, 94, 95, 96, 97, 162 |
7 |
Azathioprine 25 mg |
Azathioprine |
D00238, D03033 |
- |
- |
[1] 44 |
8 |
Belimumab |
Belimumab |
D03068 |
[1] TNFSF13B |
[4] Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis |
[8] 11, 43, 44, 46, 49, 51, 53, 222 |
9 |
Benralizumab |
Benralizumab |
D09874 |
[1] IL5RA |
[4] Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer |
[2] 44, 45 |
10 |
Blisibimod |
Blisibimod |
D10311 |
- |
- |
[5] 43, 44, 49, 63, 66 |
11 |
Ccx168 |
- |
- |
- |
- |
[6] 43, 44, 66, 109, 222, 223 |
12 |
Chimeric monoclonal antibody, igg4 subtype |
- |
- |
- |
- |
[2] 43, 44 |
13 |
Corticosteroid |
- |
- |
- |
- |
[10] 13, 42, 43, 44, 45, 66, 84, 96, 97, 222 |
14 |
Corticosteroid and azathioprine |
Azathioprine |
D00238, D03033 |
- |
- |
[4] 42, 43, 44, 45 |
15 |
Cyclophosphamide |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[43] 13, 14, 16, 19, 20, 26, 28, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 56, 60, 61, 62, 65, 66, 84, 85, 93, 96, 162, 164, 172, 222, 224, 265, 274, 283, 284, 285, 288, 326, 331 |
16 |
Cyclophosphamidum |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[1] 44 |
17 |
Cyclophosphamidum 500 mg |
Cyclophosphamide |
D00287, D07760 |
- |
- |
[1] 44 |
18 |
Endoxan® 500 mg |
- |
- |
- |
- |
[1] 44 |
19 |
Galen® tablet |
- |
- |
- |
- |
[2] 43, 44 |
20 |
Glucocorticoid (gc) |
- |
- |
- |
- |
[2] 43, 44 |
21 |
Glucocorticoids |
- |
- |
- |
- |
[6] 40, 41, 43, 44, 60, 62 |
22 |
Glucocorticoids (gc) |
- |
- |
- |
- |
[2] 43, 44 |
23 |
Glucocorticoids - reduced dose |
- |
- |
- |
- |
[2] 43, 44 |
24 |
Glucocorticoids - standard dose |
- |
- |
- |
- |
[2] 43, 44 |
25 |
Gusperimus |
Gusperimus |
D08032 |
- |
- |
[1] 44 |
26 |
Ifx-1 |
- |
- |
- |
- |
[3] 43, 44, 269 |
27 |
Mabthera® |
- |
- |
- |
- |
[6] 13, 35, 43, 44, 46, 93 |
28 |
Mepolizumab |
Mepolizumab |
D04923 |
[1] IL5 |
[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
[4] 44, 45, 98, 162 |
29 |
Mesna |
Coenzyme m |
- |
- |
- |
[9] 13, 44, 45, 49, 51, 60, 65, 96, 164 |
30 |
Metex 2,5 mg tabletten |
- |
- |
- |
- |
[1] 44 |
31 |
Methotrexate |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[33] 11, 13, 19, 34, 35, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 55, 56, 60, 62, 65, 84, 93, 96, 97, 162, 164, 172, 256, 271, 284, 285, 326, 331 |
32 |
Methotrexate 2.5 mg |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 44 |
33 |
Methotrexate 25 mg |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 44 |
34 |
Metoject 10 mg/ml, solution injectable en seringue pré-remplie |
Methotrexate |
D00142, D02115 |
[2] DHFR, DHFR2 |
[4] Antifolate resistance, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
[1] 44 |
35 |
Naltrexone |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[11] 6, 10, 13, 40, 41, 42, 43, 44, 45, 96, 97 |
36 |
Naltrexone hydrochloride |
Naltrexone |
D02095, D05113 |
[3] OPRD1, OPRK1, OPRM1 |
[5] Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway |
[7] 10, 40, 41, 42, 43, 44, 45 |
37 |
Pednisone |
- |
- |
- |
- |
[2] 43, 44 |
38 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[38] 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
39 |
Prednison acis® 20 mg |
- |
- |
- |
- |
[2] 43, 44 |
40 |
Prednison acis® 5 mg |
- |
- |
- |
- |
[2] 43, 44 |
41 |
Prednisone |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[43] 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
42 |
Prednisone tablets, usp |
Prednisone |
D00473 |
[1] NR3C1 |
[1] Neuroactive ligand-receptor interaction |
[3] 41, 43, 44 |
43 |
Recombinant humanized monoclonal antibody specific for human il-5 |
- |
- |
- |
- |
[2] 44, 45 |
44 |
Reslizumab |
Reslizumab |
D08985 |
[1] IL5 |
[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
[3] 44, 45, 98 |
45 |
Rituximab |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[42] 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
46 |
Rituximab (arm a) |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[2] 43, 44 |
47 |
Rituximab (arm b) |
Rituximab |
D02994 |
[1] MS4A1 |
[1] Hematopoietic cell lineage |
[2] 43, 44 |
48 |
Ro0452294/v01 |
- |
- |
- |
- |
[2] 43, 44 |
49 |
Ro0452294/v02 |
- |
- |
- |
- |
[3] 35, 43, 44 |
50 |
Same |
Ademetionine |
D07128 |
- |
- |
[15] 6, 14, 22, 43, 44, 46, 47, 49, 50, 60, 84, 93, 96, 97, 172 |
51 |
Sb-240563 |
- |
- |
- |
- |
[3] 44, 45, 98 |
52 |
Sb-240563 (mepolizumab) |
Mepolizumab |
D04923 |
[1] IL5 |
[13] Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Intestinal immune network for IgA production, JAK-STAT signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation |
[2] 44, 45 |
53 |
Sulfamethoxazole |
Sulfamethoxazole |
D00447 |
- |
- |
[4] 44, 49, 85, 299 |
54 |
Trimethoprim |
Trimethoprim |
D00145, D06236 |
- |
- |
[6] 36, 44, 49, 60, 85, 299 |
55 |
Trimethoprim sulfamethoxazole |
Sulfamethoxazole |
D00447 |
- |
- |
[1] 44 |
56 |
Yellow fever vaccine |
Yellow fever vaccine |
D06347 |
- |
- |
[7] 40, 44, 46, 50, 51, 52, 53 |
57 |
Yellow fever vaccine (17d) |
Yellow fever vaccine |
D06347 |
- |
- |
[7] 40, 44, 46, 50, 51, 52, 53 |